Anika Therapeutics (ANIK) Operating Expenses (2010 - 2026)

Anika Therapeutics (ANIK) has reported Operating Expenses for 17 consecutive years, with $18.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Expenses fell 1.36% year-over-year to $18.3 million in Q2 2026; TTM through Jun 2026 was $80.1 million, a 7.08% increase from a year earlier, with the FY2025 full-year figure at $74.9 million, down 7.7% from the prior year.
• Operating Expenses was $18.3 million for Q2 2026 at Anika Therapeutics, down from $24.5 million in the prior quarter.
• Over five years, Operating Expenses peaked at $35.4 million in Q1 2023 and troughed at -$18.9 million in Q4 2023.
• A 5-year average of $19.4 million and a median of $20.5 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses sank 146.33% in 2022 and soared 194.2% in 2024, its largest moves.
• Over 5 years, Operating Expenses stood at -$12.6 million in 2022, then tumbled by 49.9% to -$18.9 million in 2023, then jumped by 194.2% to $17.8 million in 2024, then grew by 3.94% to $18.5 million in 2025, then decreased by 1.31% to $18.3 million in 2026.
• The last three Operating Expenses figures came in at $18.3 million (Q2 2026), $24.5 million (Q1 2026), and $18.5 million (Q4 2025), per Business Quant data.